학술논문
Efficacy and safety of degludec U100 versus glargine U300 for the early postoperative management of patients with type 2 diabetes mellitus undergoing coronary artery bypass graft surgery: A non‐inferiority randomized trial.
Document Type
Article
Author
Source
Subject
*DRUG efficacy
*CORONARY artery bypass
*INSULIN derivatives
*BLOOD sugar monitoring
*GLYCEMIC control
*POSTOPERATIVE care
*SURGERY
*PATIENTS
*MANN Whitney U Test
*FISHER exact test
*TYPE 2 diabetes
*RANDOMIZED controlled trials
*DESCRIPTIVE statistics
*HYPOGLYCEMIA
*CHI-squared test
*STATISTICAL hypothesis testing
*STATISTICAL sampling
*DATA analysis software
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0742-3071
Abstract
Aims: To compare the efficacy and safety of degludec U100 versus glargine U300 for the early postoperative management of patients with type 2 diabetes mellitus (T2D) undergoing coronary artery bypass graft (CABG) surgery. Methods: A total of 239 patients were randomly assigned (1:1) to receive a basal‐bolus regimen in the early postoperative period using degludec U100 (n = 122) or glargine U300 (n = 117) as basal and glulisine before meals. The primary outcome was mean differences between groups in their daily BG concentrations. The major safety outcome was the occurrence of hypoglycemia. Results: There were no differences in mean daily BG concentrations (157 vs. 162 mg/dl), mean percentage of readings within target BG of 70–180 mg/dl (74% vs. 73%), daily basal insulin dose (19 vs. 21 units/day), length of stay (median [IQR]: 9 vs. 9 days), or hospital complications (21.3% vs. 21.4%) between treatment groups. There were no differences in the proportion of patients with BG <70 mg/dl (15.6% vs. 23.1%) or <54 mg/dl (1.6% vs. 4.3%) between degludec‐100 and glargine‐300 groups. Conclusions: Treatment with degludec U100 is as effective and safe as glargine U300 for the early postoperative hospital management of patients with T2D undergoing CABG. [ABSTRACT FROM AUTHOR]